LOSCOCCO, GIUSEPPE GAETANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.469
AS - Asia 2.276
EU - Europa 1.933
SA - Sud America 367
AF - Africa 46
OC - Oceania 36
Totale 7.127
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.412
RU - Federazione Russa 916
CN - Cina 713
SG - Singapore 658
IT - Italia 332
HK - Hong Kong 301
BR - Brasile 293
KR - Corea 270
IE - Irlanda 121
VN - Vietnam 120
FI - Finlandia 97
DE - Germania 82
SE - Svezia 82
GB - Regno Unito 81
CH - Svizzera 59
NL - Olanda 57
IN - India 52
ID - Indonesia 41
CA - Canada 40
AU - Australia 36
FR - Francia 35
JO - Giordania 32
AR - Argentina 28
ES - Italia 26
JP - Giappone 20
EC - Ecuador 17
TW - Taiwan 17
MX - Messico 12
BD - Bangladesh 10
CI - Costa d'Avorio 10
AT - Austria 9
GR - Grecia 8
ZA - Sudafrica 8
BJ - Benin 7
MA - Marocco 7
UA - Ucraina 7
CZ - Repubblica Ceca 6
PY - Paraguay 6
CL - Cile 5
CO - Colombia 5
TR - Turchia 5
VE - Venezuela 5
EG - Egitto 4
IQ - Iraq 4
KZ - Kazakistan 4
MY - Malesia 4
PE - Perù 4
PL - Polonia 4
UY - Uruguay 4
UZ - Uzbekistan 4
KE - Kenya 3
SA - Arabia Saudita 3
AE - Emirati Arabi Uniti 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
IL - Israele 2
LT - Lituania 2
LU - Lussemburgo 2
LV - Lettonia 2
NP - Nepal 2
OM - Oman 2
PH - Filippine 2
PK - Pakistan 2
AL - Albania 1
AZ - Azerbaigian 1
BB - Barbados 1
CY - Cipro 1
DK - Danimarca 1
GE - Georgia 1
HU - Ungheria 1
JM - Giamaica 1
MU - Mauritius 1
NG - Nigeria 1
PS - Palestinian Territory 1
RO - Romania 1
SI - Slovenia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
UG - Uganda 1
YT - Mayotte 1
Totale 7.127
Salva come PNG Salva come JPEG
Città #
Santa Clara 954
Singapore 467
Hefei 306
Seoul 269
Hong Kong 266
Ashburn 258
Dublin 121
Fairfield 101
Chandler 96
Beijing 73
Moscow 64
Bern 59
Houston 54
Buffalo 53
Los Angeles 51
Florence 48
Helsinki 48
Ho Chi Minh City 46
Munich 43
Altamura 42
Kent 42
Woodbridge 42
Lawrence 41
Seattle 39
New York 35
London 33
Melbourne 33
Cambridge 31
Jakarta 29
São Paulo 26
Turku 26
Wilmington 26
Princeton 25
Shanghai 24
Boston 23
Dallas 22
Hanoi 22
Mumbai 22
Paris 22
Lappeenranta 21
Milan 15
Barcelona 14
Bengaluru 14
Taipei 14
Ealing 12
Ann Arbor 11
Abidjan 10
Boardman 10
Fiesole 10
The Hague 10
Tokyo 10
Rio de Janeiro 9
Rome 9
San Diego 9
Toronto 9
Bremen 8
Brooklyn 8
City of London 8
Falkenstein 8
Guayaquil 8
Hamilton 8
Amsterdam 7
Campinas 7
Cotonou 7
Düsseldorf 7
Modena 7
Andover 6
Chicago 6
Clifton 6
Curitiba 6
Frankfurt am Main 6
Goiânia 6
Haiphong 6
Johannesburg 6
Medford 6
Montreal 6
Prague 6
Redondo Beach 6
San Jose 6
Siena 6
Thessaloniki 6
Vancouver 6
Vienna 6
Amman 5
Biên Hòa 5
Casablanca 5
Guangzhou 5
Guarulhos 5
Hangzhou 5
Phoenix 5
Rohtak 5
The Dalles 5
Tianjin 5
Washington 5
Yubileyny 5
Belo Horizonte 4
Brasília 4
Cagliari 4
Castel Maggiore 4
Hillsboro 4
Totale 4.434
Salva come PNG Salva come JPEG
Nome #
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 211
Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms 185
Essential Thrombocythemia 178
A case of disseminated Blastic Plasmocytoid Dendritic Cell Neoplasm 178
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera 175
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative 169
Kaposi Sarcoma in a patient treated with Ruxolitinib 168
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 163
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis 162
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 158
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis 152
CALR mutation burden in essential thrombocythemia and disease outcome 148
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 144
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis 144
Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm 138
Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency≤ 1% 138
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 137
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases 134
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera 133
Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis 130
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial 128
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis 127
Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement 127
A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease 127
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 125
Mutations and thrombosis in essential thrombocythemia 124
Successful use of caplacizumab in a case of refractory acquired thrombotic thrombocytopenic purpura following subacute thyroiditis 122
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 120
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia 119
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients 119
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis 116
One thousand patients with essential thrombocythemia: the Florence-CRIMM experience 115
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis 114
A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count 110
BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma 110
Impact of mutational profile on the management of myeloproliferative neoplasms: A short review of the emerging data 107
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates 106
The HScore for secondary hemophagocytic lymphohistiocytosis, calculated without a marrow biopsy, is consistently low in patients with COVID-19 105
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera 103
Myeloid sarcoma: more and less than a distinct entity 103
Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia 102
Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities 101
T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker 97
Integration of molecular information in risk assessment of patients with myeloproliferative neoplasms 97
Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2‐ and CALR‐mutated essential thrombocythemia—A Mayo Clinic study of 200 pregnancies 95
Visceral Leishmaniasis 91
Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19 89
Skin Involvement by Hematological Neoplasms with Blastic Morphology: Lymphoblastic Lymphoma, Blastoid Variant of Mantle Cell Lymphoma and Differential Diagnoses 89
Bone marrow involvement in small cell lung cancer 81
Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis 79
Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives 77
Chronic myeloproliferative neoplasms with concomitant CALR mutation and BCR::ABL1 translocation: diagnostic and therapeutic implications of a rare hybrid disease 77
Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases 74
When and how to transplant in myelofibrosis – recent trends 68
Hepatoid thymic carcinoma in a polycythemia vera patient treated with ropeginterferon Alfa-2b: Clinical, histopathological and molecular correlates 67
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes 67
PCM1::JAK2 myeloproliferative neoplasm suggested by bone marrow histopathological features 58
Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial 53
Imatinib is effective in some PDGFRA/B‐negative hypereosinophilic syndromes: A step closer to unveiling underlying mechanisms 51
Neutrophil/lymphocyte ratio identifies low‐risk polycythaemia vera patients for early Ropeginterferon alfa‐2b therapy 51
Editorial: Biological and clinical implications of the mutational landscape in myeloproliferative neoplasms 51
Thrombosis‐Driven Disease Progression in JAK2‐Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk‐Based Management 49
Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives 48
Clinical and Prognostic Correlates of the Reticulin-Collagen-Osteosclerosis (RCO) Score in Primary Myelofibrosis 41
TP53 Mutations in Myeloproliferative Neoplasms: Context‐Dependent Evaluation of Prognostic Relevance 8
null 2
null 1
Totale 7.236
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.996
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.996
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202133 0 0 0 0 0 3 2 6 8 4 8 2
2021/2022143 1 0 1 2 3 3 0 40 15 3 30 45
2022/2023626 51 117 40 29 28 88 68 30 56 12 15 92
2023/2024501 28 35 58 24 56 68 22 93 9 47 36 25
2024/20253.020 85 236 156 403 805 458 115 142 119 101 172 228
2025/20262.636 479 627 624 509 382 15 0 0 0 0 0 0
Totale 7.236